Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $20
Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $18 to $20.
Login to comment